Shire (SHPGY) Files Suits to Protect VYVANSE Patents
Tweet
Share
E-mailGet Alerts SHPGY Hot Sheet
Join SI Premium – FREE
Shire plc (Nasdaq: SHPGY) has filed lawsuits in the U.S. District Court for the District of New Jersey against each of Amneal Pharmaceuticals, LLC and Sandoz, Inc., for infringement of certain of Shire's VYVANSE patents.
The lawsuits were initiated in response to Abbreviated New Drug Applications filed by Amneal and Sandoz seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.
The lawsuits were initiated in response to Abbreviated New Drug Applications filed by Amneal and Sandoz seeking FDA approval to market and sell generic versions of all currently approved doses of VYVANSE.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
